Navigation Links
TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
Date:2/14/2008

- Plan Also Calls for Expansion of Business Development, Streamlining of

Operations -

- Company to Host Conference Call/Webcast at 11 a.m. EST Today -

LA JOLLA, Calif., Feb. 14 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced a strategic plan for 2008 with a focus on clinical development activities to maximize the value of the company's versatile lead compounds: AMPA/kainate receptor antagonists tezampanel and NGX426 and muscarinic agonist NGX267. The plan also calls for the expansion of business development initiatives to evaluate partnership opportunities across the company's product pipeline and the streamlining of operations through an expense-reduction program.

Specifically, the company intends to:

Maximize Value of Versatile Lead Compounds

AMPA/kainate receptor antagonists

-- Conduct a Clinical Guidance meeting with the U.S. Food and Drug

Administration (FDA) in the first half of the year to discuss the

efficacy results from the recently completed Phase II clinical

trial of tezampanel in acute migraine headache. As reported last

October, tezampanel met its primary endpoint of headache pain

relief in a double-blind, placebo-controlled, Phase IIb trial in

306 patients with acute migraine. Depending on the outcome of the

meeting, the company intends to conduct an end-of-Phase II meeting

with the FDA in the second half of 2008.

-- Initiate a Phase II trial of tezampanel in muscle spasticity and

rigidity secondary to spinal cord trauma in the second half of the

year. This trial will b
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
2. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
3. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
4. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
5. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
8. PTC Therapeutics Announces Publication of Preclinical Data in PNAS
9. ImaRx Therapeutics Transitions Business Strategy
10. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
11. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the ... sponsored by Mission Pharmacal Company. The survey, conducted by ... support community, revealed that 74 percent of osteoporosis patients ... form other than a pill or a tablet. ...
(Date:1/15/2014)... 2014  Novation, the leading health care supply chain expertise, ... reseller (VAR) national contracts that expand its portfolio to ... lower costs. These include manufacturer product and service agreements, ... and ongoing IT consulting support. New ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
(Date:7/11/2014)... Europe is one of the largest ... hence, irrigated land area. The agricultural sector is a ... around 30.0% of the total water use. The scale ... southern region, but far from negligible in most northern ... over 60.0% of the water use in most countries, ...
(Date:7/11/2014)... understand the best available treatment for patients, from a ... costly for taxpayers than the existing clinical trial process, ... Staa, carried out while he was a member of ... now based at The University of Manchester,s Health eResearch ... HTA ) today (Friday 11 July) looked at the ...
(Date:7/11/2014)... Salt Lake City, UT (PRWEB) July 11, 2014 ... hard at work at the Kilimanjaro Kids Community in Tanzania. ... children, 40 goats, 150 chickens, and two cows. HOP Founder, ... and provide education for some of the orphaned children he ... week, the HOP Team visited the children, who have all ...
(Date:7/11/2014)... being prescribed exercise as medicine, according to a ... activity is essential to reducing the risk of ... from QUT,s Institute of Health and Biomedical Innovation, ... physical and mental health, health professionals should be ... Professor Anderson and QUT,s Dr Charlotte Seib co-authored ...
(Date:7/11/2014)... July 11, 2014 Emily Johnson, owner of the ... Her fitness boot camp has held two charity workout ... on Saturday, July 26th, from 7:15 - 8:30 at Col Summers ... first charity boot camp session raised $510 for Medical Teams International. ... non-profit I Have a Dream. On July 26th, Johnson and ...
Breaking Medicine News(10 mins):Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 2Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 3Health News:Better use of electronic health records makes clinical trials less expensive 2Health News:Human Outreach Project Sees Incredible Progress in the Kilimanjaro Kids Community 2Health News:Exercise is the best medicine: QUT study 2Health News:Portland Fit Body Boot Camp Invites Public to Fitness Boot Camp Session Benefiting Children’s Cancer Association 2Health News:Portland Fit Body Boot Camp Invites Public to Fitness Boot Camp Session Benefiting Children’s Cancer Association 3
... Council will launch its 2009 June National Safety Month with free enrollment ... , "Alive at ... "First Aid and CPR with AED," basic training ... "Alive at 25 Parent Program" is an engaging, science-based course that educates ...
... is certain: there,s no place like home. Now, a study ... is true for rats. Although inner city rodents appear to ... majority of their lives. , Like any major city, Baltimore ... But scientists from the Johns Hopkins Bloomberg School of Public ...
... staff connect using technology powered by 100 ... solutionsJERICHO, N.Y., May 26 Optimum Lightpath, ... for New York metropolitan area businesses, today ... solution available exclusively through Optimum Lightpath to ...
... the two illnesses , , TUESDAY, May 26 (HealthDay News) ... heart disease has been discovered by German scientists. , ... has been known for years, but a genetic link ... Kiel team found that the two diseases share a ...
... Scheduled for Monday June 1 at 1:00 PM ET ... Calif., May 26 Sunesis Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of new oncology therapeutics, today announced ... 2 clinical trials in frontline acute myeloid leukemia (AML) ...
... dental expert notes importance of regular oral care to protect ... Results from a 2008 Gallup-Healthways poll(1) show that 42 percent ... 12 months, even though the American Dental Association recommends having ... percent of all Americans responded that they did not see ...
Cached Medicine News:Health News:National Safety Council Launches June National Safety Month With Free Training 2Health News:Optimum Lightpath(SM) and GetWellNetwork(R) Transform Hospital Bedside Care with Launch of Interactive Patient Care Service 2Health News:Optimum Lightpath(SM) and GetWellNetwork(R) Transform Hospital Bedside Care with Launch of Interactive Patient Care Service 3Health News:Optimum Lightpath(SM) and GetWellNetwork(R) Transform Hospital Bedside Care with Launch of Interactive Patient Care Service 4Health News:Gum Disease, Heart Disease Share Genetic Link 2Health News:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO 2Health News:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO 3Health News:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO 4Health News:Hispanics Placing Their Oral Health at Risk by Cutting Back on Routine Dental Care 2Health News:Hispanics Placing Their Oral Health at Risk by Cutting Back on Routine Dental Care 3
Anodized aluminum. Durable and lightweight with built-in protection against rust. Security locks ensure against accidental opening. Silicone matting/V-strips and bumper guards hold instruments in pla...
... Storage in bottom of ... accessories, etc. Anodized aluminum. Durable ... against rust. Security locks ensure ... and bumper guards hold instruments ...
Size: 3 x 6 inches. Depth: 1 inch. Sterilizable plastic tray with silicone matting for supporting and protecting instruments....
Size: 6 x 10 inches. Depth: 7 inches. Sterilizable plastic tray with silicone matting for supporting and protecting instruments....
Medicine Products: